Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07657468

Phase II, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids as an Adjunct to Morphine in Acute Postoperative Pain

This is a single-center, randomized, double-blind, placebo-controlled, parallel-group proof-of-concept study to evaluate the analgesic efficacy and safety of omega-3 fatty acids as an adjunct to morphine for acute postoperative pain following laparoscopic cholecystectomy.

Patients will receive either omega-3 fatty acid supplementation or a placebo before and after surgery. At the end of surgery, a loading dose of morphine of 0.04 mg/kg body weight will be administered intravenously as a bolus in both groups. The primary endpoint will be the total amount of rescue morphine used during the first 24 postoperative hours.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

About this study

Currently, the most widely used drugs for treating post-surgical pain are opioids, such as morphine. Morphine works primarily by activating specific opioid receptors, providing significant pain relief but also causing side effects that limit its use.

Preclinical studies in our laboratory have shown that combined treatment with morphine and omega-3 fatty acids produces an additive enhancement of morphine's analgesic effect, mediated by the opioid pathway. Furthermore, we observed that this combined treatment prevents development of tolerance to morphine's analgesic effect and reduces some of the drug's adverse effects.

In order to reduce morphine dose and decrease or avoid morphine's side effects, the present study was designed to administer omega-3 fatty acids as an adjunct to morphine for acute postoperative pain following laparoscopic cholecystectomy.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able to provide written informed consent prior to any study procedures;
  • Able to communicate clearly with the Investigator and staff;
  • Males and females aged 18 to 65;
  • American Society of Anesthesiologists (ASA) risk class of I to II;
  • Patients with an indication for laparoscopic cholecystectomy.

Exclusion criteria

  • Patients with reduced kidney function (serum creatinine level above 2 mg/dl).
  • Sensitive to local anesthetics.
  • A history of hepatic insufficiency.
  • Chronic pain.
  • Patients with diabetes.
  • Patients with Body Mass Index (BMI) greater than 35 kg/m2.
  • Daily intake of analgesics or corticosteroids.
  • Patients with Inflammatory bowel disease.
  • Chronic opioid use.

Treatment and study plan

Omega-3 fatty acids + Morphine group

Drug

The omega-3 fatty acids will be given twice before surgery (1680 mg/day) once on the day of surgery (840 mg) with 0,04 mg/kg morphine, and twice the day after surgery (1680 mg/day). It will be administered with lunch or dinner.

Other names: Active treatment for post-operative pain

Placebo+ Morphine group

Other

The placebo will be given twice before surgery (1680 mg/day) once on the day of surgery (840 mg) with 0,04 mg/kg morphine, and twice the day after surgery (1680 mg/day). It will be administered with lunch or dinner.

Other names: Post-operative placebo for pain

Primary outcomes

  1. Total Morphine Requirement

    Time frame: 24hs

    Total morphine requirement in the 24 hours post-surgery.

Secondary outcomes

  1. Average Pain Score

    Time frame: 24 hs

  2. Average Nausea Score

    Time frame: 24 hs

  3. Average Pruritus Score

    Time frame: 24 hs

  4. Average Vomiting Score

    Time frame: 24 hs

  5. Average Respiratory Depression Score

    Time frame: 24hs

  6. Average Urinary Retention Score

    Time frame: 24 hs

Study contacts

Contact information is provided by the study sponsor or research team.

Carlos Laino, Ph pharmacology

CONTACT

[email protected]

+5493804391553

Sponsors and collaborators

Lead sponsor

National University of La Rioja

Other

Registry information

Acronym: O3MORPH

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jun 18, 2026
Registry last updated
Jun 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.